» Articles » PMID: 35674675

Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza

Abstract

Emerging respiratory viruses are major health threats due to their potential to cause massive outbreaks. Over the past 2 years, the coronavirus disease 2019 (COVID-19) pandemic has caused millions of cases of severe infection and deaths worldwide. Although natural and vaccine-induced protective immune mechanisms against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been increasingly identified, the factors that determine morbimortality are less clear. Comparing the immune signatures of COVID-19 and other severe respiratory infections such as the pandemic influenza might help dissipate current controversies about the origin of their severe manifestations. As such, identifying homologies in the immunopathology of both diseases could provide targets for immunotherapy directed to block shared pathogenic mechanisms. Meanwhile, finding unique characteristics that differentiate each infection could shed light on specific immune alterations exploitable for diagnostic and individualized therapeutics for each case. In this study, we summarize immunopathological aspects of COVID-19 and pandemic influenza from the perspective of cytokine storms as the driving force underlying morbidity. Thereby, we analyze similarities and differences in the cytokine profiles of both infections, aiming to bring forward those molecules more attractive for translational medicine and drug development.

Citing Articles

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.


Diagnostic Markers of Severe COVID-19 and Community-Acquired Pneumonia in Children From Southern India.

Damodar T, Lodha L, Suran S, Prabhu N, Jose M, Kinhal U Microbiol Immunol. 2025; 69(3):174-181.

PMID: 39812381 PMC: 7617320. DOI: 10.1111/1348-0421.13198.


Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza.

West A, Harpur C, Le Page M, Lam M, Hodges C, Ely L J Infect Dis. 2023; 230(2):e384-e394.

PMID: 38060822 PMC: 11326819. DOI: 10.1093/infdis/jiad566.


In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury.

Giannakopoulos S, Strange D, Jiyarom B, Abdelaal O, Bradshaw A, Nerurkar V PLoS Pathog. 2023; 19(5):e1011409.

PMID: 37200377 PMC: 10231791. DOI: 10.1371/journal.ppat.1011409.


Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A.

Santos A, Martel F, Freire C, Ferreira B Bioengineering (Basel). 2022; 9(12).

PMID: 36551022 PMC: 9816944. DOI: 10.3390/bioengineering9120816.


References
1.
Costagliola G, Spada E, Consolini R . Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19. Immun Inflamm Dis. 2021; 9(2):331-339. PMC: 8014746. DOI: 10.1002/iid3.404. View

2.
Al-Samkari H, Berliner N . Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2017; 13:27-49. DOI: 10.1146/annurev-pathol-020117-043625. View

3.
Opal S . The evolution of the understanding of sepsis, infection, and the host response: a brief history. Crit Care Nurs Clin North Am. 2011; 23(1):1-27. DOI: 10.1016/j.ccell.2010.12.001. View

4.
Locatelli F, Jordan M, Allen C, Cesaro S, Rizzari C, Rao A . Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822. DOI: 10.1056/NEJMoa1911326. View

5.
Caroppo F, Biolo G, Belloni Fortina A . SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab. J Eur Acad Dermatol Venereol. 2020; 34(8):e368. PMC: 7272929. DOI: 10.1111/jdv.16619. View